← All trials
NCT03998969
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2016
- Primary completion
- Dec 11, 2018
- Completion date
- Dec 11, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Seoul National UniversityLead sponsor
- Dong-A PharmaceuticalCollaborator
- Seoul National UniversityReponsible party - principal investigator
- Seoul National UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.